The promise of CAR T-cell therapy comes at a cost

Australian researchers are close to making an exorbitantly expensive life saving immunotherapy treatment cheaper and more accessible to thousands of leukaemia and lymphoma patients whose disease has returned despite having bone marrow transplants. The treatment involves collecting T-cells from a simple blood draw and then genetically engineering them in a laboratory to produce chimeric antigen ...